ACCEPTANCE OF MIRENA IN HEAVY MENSTRUAL BLEEDING : A PROSPECTIVE STUDY

Abstract

The phrase "abnormal uterine bleeding" (AUB) refers to a broad spectrum of irregularities in
the menstrual cycle, such as differences in the volume, regularity, frequency, and length of flow
outside of pregnancy.
Excessive monthly blood loss, known as heavy menstrual bleeding, has a detrimental effect on a
woman's social, physical, emotional, and/or economical well-being. It might show up alone or
in combination with other symptoms. First line option includes LNG-IUS, hormonal medications
like combined oral contraceptive pills, cyclical progesterons, non-hormonal medications like
tranexamic acid, NSAIDS. The T-shaped, MIRENA is a cylindrical device that controls the pace
at which hormones are released. It comprises 52 milligrams of levonorgestrel enclosed in a
rate-regulating membrane. Initially, levonorgestrel is released at a rate of 20 µg per 24 hours;
this drops to 11 µg per 24 hours after five years, yielding an average daily release rate of 14 µg
over the device's lifetime. A prospective research was conducted on patients who were
enrolled from February 2017 to February 2018 at the gynecology and obstetrics department of
Rohilkhand Medical College and Hospital in Bareilly. We made use of the patient's data
regarding her menstrual cycle and related adverse effects. It was utilized for follow up of
patient. Pictorial Blood Loss Assessment Chart, weight, and hemoglobin were used to measure
blood loss during each menstrual cycle in addition to other information.